Stocks and Investing Stocks and Investing
Tue, July 2, 2024
Mon, July 1, 2024

Raghuram Selvaraju Reiterated (URGN) at Strong Buy and Held Target at $60 on, Jul 1st, 2024


Published on 2024-10-28 12:12:24 - WOPRAI, Raghuram Selvaraju
  Print publication without navigation


Raghuram Selvaraju of HC Wainwright & Co., Reiterated "UroGen Pharma Ltd." (URGN) at Strong Buy and Held Target at $60 on, Jul 1st, 2024.

Raghuram has made no other calls on URGN in the last 4 months.



There are 2 other peers that have a rating on URGN. Out of the 2 peers that are also analyzing URGN, 0 agree with Raghuram's Rating of Hold.



These are the ratings of the 2 analyists that currently disagree with Raghuram


  • Leland Gershell of "Oppenheimer" Maintained at Buy with Increased Target to $40 on, Friday, June 14th, 2024
  • Matthew Kaplan of "Ladenburg Thalmann" Maintained at Strong Buy with Increased Target to $54 on, Friday, June 14th, 2024
Contributing Sources